We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Review article: vascular effects of PPARs in the context of NASH.
- Authors
Guixé‐Muntet, Sergi; Biquard, Louise; Szabo, Gyongyi; Dufour, Jean‐François; Tacke, Frank; Francque, Sven; Rautou, Pierre‐Emmanuel; Gracia‐Sancho, Jordi
- Abstract
Summary: Background: Peroxisome proliferator‐activated receptors (PPARs) are ligand‐activated transcription factors known to regulate glucose and fatty acid metabolism, inflammation, endothelial function and fibrosis. PPAR isoforms have been extensively studied in metabolic diseases, including type 2 diabetes and cardiovascular diseases. Recent data extend the key role of PPARs to liver diseases coursing with vascular dysfunction, including nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Aim: This review summarises and discusses the pathobiological role of PPARs in cardiovascular diseases with a special focus on their impact and therapeutic potential in NAFLD and NASH. Results and Conclusions: PPARs may be attractive for the treatment of NASH due to their liver‐specific effects but also because of their efficacy in improving cardiovascular outcomes, which may later impact liver disease. Assessment of cardiovascular disease in the context of NASH trials is, therefore, of the utmost importance, both from a safety and efficacy perspective.
- Subjects
PEROXISOME proliferator-activated receptors; NON-alcoholic fatty liver disease; TRANSCRIPTION factors; TYPE 2 diabetes; CARDIOVASCULAR diseases
- Publication
Alimentary Pharmacology & Therapeutics, 2022, Vol 56, Issue 2, p209
- ISSN
0269-2813
- Publication type
Article
- DOI
10.1111/apt.17046